Saw Palmetto Toxicities
Saw palmetto is generally well-tolerated with minimal toxicity, but the primary concern is increased bleeding risk, particularly when combined with antiplatelet agents like aspirin, especially in elderly patients.
Bleeding Risk
The most clinically significant toxicity is increased bleeding time and perioperative bleeding risk 1. The mechanism involves cyclooxygenase inhibition (demonstrated in rodent models), which can lead to:
- Hematuria
- Operative bleeding complications
- Enhanced antiplatelet effects when combined with aspirin
The perioperative guideline recommends holding saw palmetto for 2 weeks before surgery 1. This is particularly critical given recent real-world data showing that concomitant aspirin use with saw palmetto is associated with significantly elevated reporting odds for hemorrhage (OR 3.89) and fatal outcomes (OR 2.87), with even higher risk in patients ≥75 years (OR 7.26 for mortality) 2. Network analysis reveals 46 shared molecular targets between saw palmetto and aspirin, particularly affecting arachidonic acid metabolism and platelet activation pathways 2.
Hepatobiliary Toxicity
Hepatobiliary disorders represent a significant safety signal in post-marketing surveillance 2. Reported events include:
- Cholestasis
- Pruritus
- Elevated liver enzymes
While rare, these events warrant monitoring in patients with pre-existing liver disease or those on hepatotoxic medications.
Gastrointestinal Effects
Mild gastrointestinal adverse effects are the most commonly reported:
- Nausea
- Epigastric discomfort
- Acute pancreatitis (rare case report) 3
The pancreatitis case involved a 61-year-old man who developed symptoms 36 hours after use, with resolution upon discontinuation 3.
Hematological Effects
Blood and lymphatic disorders emerged as disproportionate signals 2, including:
- Eosinophilia
- Confusion (possibly related to bleeding complications)
Overall Safety Profile from Clinical Trials
Large-scale randomized controlled trials demonstrate reassuring safety data:
- No significant differences in serious adverse events between saw palmetto and placebo (5.4% vs 9.7%, p=0.31) 4
- No dose-dependent toxicity at doses up to 960 mg daily (3× standard dose) over 18 months 5
- No significant laboratory abnormalities except minor changes in total bilirubin and potassium 4
- No impact on sexual function, vital signs, or prostate examination findings 5, 4
Clinical Pitfalls and Recommendations
Key caveat: While controlled trials show excellent safety, real-world post-marketing data reveal concerning signals for bleeding and hepatobiliary events that may not have been captured in shorter-term studies 2.
High-risk populations requiring vigilance:
- Elderly patients (≥75 years)
- Patients on antiplatelet or anticoagulant therapy
- Patients with pre-existing liver disease
- Perioperative patients
Practical approach:
- Discontinue 2 weeks before elective surgery 1
- Avoid in patients on aspirin or anticoagulants, particularly elderly
- Monitor liver function if long-term use is planned
- Counsel patients about potential bleeding risk
The discrepancy between controlled trial safety and real-world signals likely reflects the difference between selected trial populations and broader real-world use in older, multimorbid patients on multiple medications 2.